Described is a low voltage, pulsed electrical stimulation device for modulating the expression of sestrin, a useful protein, by tissues. Also described are methods of enhancing expression of sestrins in cells, particularly a method of stimulating the expression and/or release of sestrins in a cell having a gene encoding a sestrin, wherein the method includes applying a bioelectric signal comprising a biphasic constant current at a frequency of, within 15%, 10 Hz to 20 Hz, with a pulse width of, within 15%, 300 to 400 microseconds (μsec).
Described is a low voltage, pulsed electrical stimulation device for modulating the expression of NANOG, a useful protein, by cells and tissues. Also described are methods of enhancing expression of NANOG in cells, particularly a method of stimulating the expression and/or release of NANOG in a cell having a gene encoding NANOG, wherein the method includes applying a bioelectric signal of, within 15%, 1 mA to about 5 mA, 20 pulses per second, at 400 microsecond pulse duration to the cell (e.g., directly, indirectly, or wirelessly).
Described is a low voltage, pulsed electrical stimulation device for modulating the expression of sirtuin (“SIRT”), a useful protein, by tissues. Also described are methods of enhancing expression of SIRT in cells, particularly a method of stimulating the expression and/or release of SIRT in a cell having a gene encoding SIRT, wherein the method includes applying a bioelectric signal of, within 15%, 50 μA to about 500 μA, 20 pps, at 400 μsec pulse duration to the cell (e.g., directly, indirectly, or wirelessly). In order to downregulate expression of SIRT, the at least one bioelectric signal has a current of at least about 1 mA, as measured at the level of the living cells.
Age is an important predictor of neuromuscular recovery after peripheral nerve injury. Insulin-like growth factor 1 (IGF-1) is a potent neurotrophic factor that is known to decline with increasing age. The purpose of this study was to determine if locally delivered IGF-1 would improve nerve regeneration and neuromuscular recovery in aged animals. Young and aged rats underwent nerve transection and repair with either saline or IGF-1 continuously delivered to the site of the nerve repair. After 3 months, nerve regeneration and neuromuscular junction morphology were assessed. In both young and aged animals, IGF-1 significantly improved axon number, diameter, and density. IGF-1 also significantly increased myelination and Schwann cell activity and preserved the morphology of the postsynaptic neuromuscular junction (NMJ), These results show that aged regenerating nerve is sensitive to IGF-1 treatment. Muscle Nerve, 2009
Described are a device, system, and method for bioelectric stimulation to accelerate bone integration of an implant and/or bone graft in order to aid healing. Specifically described are devices and methods for enhancing bone integration of a body implant (e.g., a dental implant) or bone graft by modulating (e.g., stimulating) the controlled expression and/or release of selected proteins, which proteins promote osteogenesis and osseointegration via specific bioelectric signals delivered via, e.g., a specialized mouthpiece, electrodes, and/or wireless means. The description particularly relates to the acceleration of the healing of dental implants and/or bone grafts via promoting bone osteointegration more quickly with bioelectric stimulation.
Described is a low voltage, pulsed electrical stimulation device for modulating (e.g., downregulating) expression of fatty-acid-binding protein 4 (“FABP4”) protein(s) by cellular tissues. In certain embodiments, the device is further programmed or alternatively programmed to produce a bioelectric signal or signals that upregulate expression of, for example, klotho by the tissues.
Described is a low voltage, pulsed electrical stimulation device for controlling expression of growth differentiation factor 10 (“GDF10”), a useful protein, by tissues. Also described are methods of enhancing expression of GDF10 in cells, particularly a method of stimulating the expression and/or release of GDF10 in a cell having a gene encoding GDF10, wherein the method includes applying a bioelectric signal produces, as measured at the level of the target cells or tissues being stimulated 2 mA to 4 mA direct current positive to the cell (e.g., directly, indirectly, or wirelessly). Applications in the treatment of cerebral strokes, brain injuries, paralysis, brain cancer, Alzheimer's disease, dementia, anxiety, Parkinson's disease, and/or essential tremors are also disclosed.
Described is a low voltage, pulsed electrical stimulation device for controlling expression of Brain-Derived Neurotrophic Factor (“BDNF”), a useful protein, by tissues. Also described are methods of enhancing expression of BDNF in cells, particularly a method of stimulating the expression and/or release of BDNF in a cell having a gene encoding BDNF, wherein the method includes applying a bioelectric signal of from about 10 Hz to about 100 Hz (e.g., 5 Hz, 10 Hz, 40 Hz, 100 Hz, or 110 Hz) to the cell (e.g., directly, indirectly, or wirelessly). Applications in the treatment of Alzheimer's disease, depression, schizophrenia, and post-traumatic stress disorder are also disclosed.
Described is precise bioelectrical stimulation of a subject's cellular tissue with a selected bioelectric signal to modulate the expression of a peptide by the cellular tissue. More specifically, the application relates to a device that delivers a programmed bioelectric signal or signals, and associated methods for the controlled modulation of a peptide, such as vascular endothelial growth factor (VEGF) and/or hypoxia-inducible factor 1-alpha (HIF1α), or manipulation of stem cells, via precise bioelectrical signals and sequences useful in, for example, orthodontic and other procedures. The bioelectric signals have preferably been further optimized by selecting a desired pulse width for the peptide(s) to be expressed.
Described is a low voltage, pulsed electrical stimulation device (bioelectric stimulator associated with electrodes) for controlling expression of S100 protein(s) by cellular tissues. The bioelectric stimulator is useful in methods to treat a subject suffering from bladder, heart, and/or nerve tissue damage.
Described are methods of treating a mammalian subject who is intending to undergo exposure to an inoculant comprising a virus, polynucleotide(s) encoding at least a portion of the virus, and/or epitope(s) of the virus, the method including administering at least one bioelectric signal to the subject before exposure to the inoculant in such a manner as to increase the subject's T cell count and/or T helper cell count. Also described are methods of treating a mammalian subject undergoing a viral infection, the method comprising: administering bioelectric signals to the subject so as to upregulate expression of SDF-1 in the subject, upregulate expression of PDGF in the subject, upregulate stem cell proliferation in the subject, and upregulate expression of klotho in the subject; reducing inflammation in the subject, and administering bioelectric signals to the subject so as to stimulate regeneration of the subject's lungs and blood vessels.
A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61H 1/00 - Apparatus for passive exercisingVibrating apparatusChiropractic devices, e.g. body impacting devices, external devices for briefly extending or aligning unbroken bones
Described is a low voltage, pulsed electrical stimulation device for controlling expression of sonic hedgehog (“Shh”), a useful protein, by tissues. Also described are methods of enhancing expression of sonic hedgehog in cells, particularly a method of stimulating the expression and/or release of Shh in a cell having a gene encoding Shh, wherein the method includes applying a bioelectric signal of less than 50 Hz (e.g., 5 Hz, 10 Hz, or 20 Hz) at a pulse width duration of, e.g., 1 ms, to the cell (e.g., directly, indirectly, or wirelessly), and wherein the amount of Shh expression enhanced by this bioelectric signal is greater than that seen with a prior art bioelectric muscle stimulation or bioelectric muscle contraction alone as may be determined by, e.g., by an analysis of the upregulation of mRNA level/GAPDH fold gene expression in the cell.
Described is a low voltage, pulsed electrical stimulation device for upregulating expression of klotho, a useful protein, by tissues. Also described are methods of enhancing expression of klotho in cells.
A skin regeneration therapy combining precise bioelectric signals, light, and biologics for skin treatment and regeneration. Precise bioelectric signals give clear instructions to the stimulated cell DNA/RNA to produce specific regenerative proteins on demand. Bioelectric signals give clear instructions to cell membranes on what to let in and what to let out and serve as an equivalent or surrogate of environmental stimuli to cause a cell action in response.
A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
Described is a low voltage, pulsed electrical stimulation device for controlling expression of, for example, follistatin, a muscle formation promotion protein, by tissues. Epicardial stimulation is especially useful for heart treatment. Follistatin controlled release is also useful for treating other ailments, such as erectile dysfunction, aortic aneurysm, and failing heart valves.
A61N 1/32 - Applying electric currents by contact electrodes alternating or intermittent currents
A61B 5/243 - Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents specially adapted for magnetocardiographic [MCG] signals
Described is a low voltage, pulsed electrical stimulation device for controlling expression of Collagen Type XVII Alpha 1 chain (COL17A1), a useful protein, by tissues. Also described are methods of COL17A1 in cells.
Described is a method of treating a subject diagnosed with cancer, breast cancer, bone cancer, lung cancer, osteoporosis, multiple myeloma, and a combination of any thereof by applying a bioelectric signal or signals that upregulate the expression of Osteoprotegerin (“OPG”) and thus beneficially effect the subject's OPG/RANKL/RANK pathway.
Described is a bioelectric stimulating device for reducing orthodontic treatment time (braces or aligners) with post-treatment stability enhancement. The device and associated methods provide a native sustainable optimal upregulated expression and/or release of an increase in the quantity of the right cells and proteins over time and in the right sequence to optimize tooth movement with the braces or aligners by accelerating bone resorption at the leading edge of the tooth during movement. This acceleration phenomenon is responsible for being able to shorten orthodontic treatment time. Following the final alignment of the teeth, the same device can utilize the native response and accelerate the tooth/bone interface stability by targeting specific cells and proteins that are responsible for bone deposition (hardening) in order to shorten the retention phase, while greatly decreasing the chance of relapse (instability).
Described is a low voltage, pulsed electrical stimulation device for controlling expression of sonic hedgehog (“Shh”), a useful protein, by tissues. Also described are methods of enhancing expression of sonic hedgehog in cells, particularly a method of stimulating the expression and/or release of Shh in a cell having a gene encoding Shh, wherein the method includes applying a bioelectric signal of less than 50 Hz (e.g., 5 Hz, 10 Hz, or 20 Hz) at a pulse width duration of, e.g., 1 ms, to the cell (e.g., directly, indirectly, or wirelessly), and wherein the amount of Shh expression enhanced by this bioelectric signal is greater than that seen with a prior art bioelectric muscle stimulation or bioelectric muscle contraction alone as may be determined by, e.g., by an analysis of the upregulation of mRNA level/GAPDH fold gene expression in the cell.
Described is a low voltage, pulsed electrical stimulation device for controlling expression of klotho, a useful protein, by tissues. Also described are methods of enhancing expression of klotho in cells.
Described is a low voltage, pulsed electrical stimulation device for controlling expression of klotho, a useful protein, by tissues. Also described are methods of enhancing expression of klotho in cells and treating a subject's kidneys.
Described is a device for preventing thrombosis formation on surfaces of a blood contact device. The device may first non-invasively scan the blood contact device and determines the highest risk thrombosis points. The device then, preferably starting with the highest risk location, delivers a succession of harmonic vibration signals or electromagnetic signals non-invasively so as to prevent clot formation at each stagnation high risk point of the blood contact device (e.g., harmonic resonance). This resonant vibration calibration tuning information is stored in an associated microprocessor. The signals are then delivered, based upon the stored information, in a loop from the signal generator, usually on a belt outside the patient, to each stagnation point in sequence from highest risk of thrombosis to lowest; again and again repeated. By delivering such energy to the blood contact device stagnation points, initiation of thrombosis formation is prevented, thus preventing the accumulation of thrombosis to a dangerous risk level for stroke, pulmonary embolism, and/or other blood clot induced ailments. This device may be used to prevent and/or treat blood clot, plaque, and/or calcification formation on any blood contact surfaces including living surfaces such as heart valves.
Described are a system and method that “reads” cancer tumors real time and custom delivers individualized bioelectric therapy to the patient. For example, the system reads a cancer tumor, and based upon this read, delivers to the subject “a confounding signal” to jam communication within that tumor. A cancer tumor may change its communication patterns and the therapy is designed to change with these patterns, attempting to always jam the relevant communication signaling pathway. The described system includes parameters not tied to communication jamming, which should also be customized to induce apoptosis to the cancer tumor. Such parameters include signals for starving a cancer tumor of blood supply and signals for changing the cancer tumor's surface proteins and/or charge so that the immune system attacks the cancer tumor.
Described is a low voltage, pulsed electrical stimulation device for reducing inflammation in a subject, which can be useful in the treatment of concussions, traumatic brain injury, cancer, and so forth.
A61N 1/372 - Arrangements in connection with the implantation of stimulators
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
Described are a system and method that utilize bioelectric signaling to balance electrical potentials in a subject's body via neuro-hormonal circuit loops, to increase elasticity of the subject's arteries to promote protein release to dampen arterial blood pressure, and to change arterial electrical charges to reduce narrowing of the arteries. The described system is designed to localize and stimulate the fibers inside the vagus nerve without inadvertent stimulation of non-baroreceptive fibers causing side effects like bradycardia and bradypnea. The system also controls release of specific proteins known to lower blood pressures including tropoelastin (known to increase elasticity in the aorta and other peripheral blood vessels).
A skin regeneration therapy combining precise bioelectric signals, light, and biologics for skin treatment and regeneration. Precise bioelectric signals give clear instructions to the stimulated cell DNA/RNA to produce specific regenerative proteins on demand. Bioelectric signals give clear instructions to cell membranes on what to let in and what to let out and serve as an equivalent or surrogate of environmental stimuli to cause a cell action in response.
A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
Described is a low voltage, pulsed electrical stimulation device for controlling expression of, for example, follistatin, a muscle formation promotion protein, by tissues. Epicardial stimulation is especially useful for heart treatment. Follistatin controlled release is also useful for treating other ailments, such as erectile dysfunction, aortic aneurysm, and failing heart valves.
A61B 5/243 - Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents specially adapted for magnetocardiographic [MCG] signals
patents